Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 15, 2015, Pages 2373-2379

  Williams, David M ^a   Stephens, Jeffrey W ^a,b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

dapagliflozin; dipeptidyl peptidase 4; fixed dose combination; saxagliptin; sodium glucose cotransporter 2

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; SAXAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ADAMANTANE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

BLOOD PRESSURE; BODY WEIGHT; CELL FUNCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN CLEARANCE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; URINARY TRACT INFECTIONS;

ADAMANTANE; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; URINARY TRACT INFECTIONS;

EID: 84942162793     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1088830     Document Type: Review

References (23)

1. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38(3):376-83
2. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebocontrolled study. Diabetes Care 2014;37(3):740-50
3. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35(7):1473-8
4. Strojek K, Yoon KH, Hruba V, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: A randomized, doubleblind, parallel-group, placebo-controlled trial. Diabetes Ther 2014;5(1):267-83
5. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebocontrolled trial. Lancet 2010;375(9733):2223-33
6. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32(9):1649-55
7. Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13(6):567-76
8. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94(12):4810-19
9. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28(4):513-23
10. Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract 2014;20(11):1187-97
11. Vakkalagadda B, Vetter M, Rana J, et al. Bioequivalence (BE) of Saxaglitpin (SAXA)/Dapagliflozin (DAPA) Fixed Dose Combination (FDC) Tablets Compared with Co-administration of the Individual Tablets. Diabetes 2015;64(Suppl 1):1254-P
12. Matthaei S, Catrinoiu D, Celinski A, et al. A Randomized, Double-Blind Trial of Saxagliptin Add-on to Dapagliflozin and Metformin. Diabetes 2015;64(Suppl 1):104-OR
13. Matthaei S, Ranetti AE, Danshi L, et al. A Randomized, Double-Blind Phase 3 Trial of Dapagliflozin Add-on to Saxagliptin and Metformin in Type 2 Diabetes. Diabetes 2015;64(Suppl 1):105-OR
14. Blonde L, Sheehan JJ, Garcia-Sanchez R, Barrett UC. Quality Measure Thresholds with Saxagliptin (SAXA) and Dapagliflozin (DAPA) Dual Therapy vs. Individual Commponents as Add-on to Metformin (MET). Diabetes 2015;64(Suppl 1):1228-P
15. The National Quality Forum. Available from: www.qualityforum.org/Home.aspx [Last accessed 12th June 2015]
16. Sjostrom CD, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes. Diab Vasc Dis Res 2015;12(5):352-8
17. Ekholm E, Hansen L, Iqbal N, et al. Combined Treatment with Saxagliptin and Dapaglflozin improves Beta-cell Function and reduces Insulin levels by Increased Insulin Clearance. Diabetes 2015;64(Supp 1):1223-P
18. Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as addon therapy to metformin plus sulfonylurea: A 24-week randomized, double-blind clinical trial. Diabetes Care 2015;38(3):365-72
19. Rohwedder K, Ekholm E, Cook W, et al. Dual Treatment with Saxagliptin and Dapgliflozin Provides a Similar Increase in Urinary Glucose Excretion With Fewer Genitourinary Infections Compare with Dapagliflozin. Diabetes 2015;64(Suppl 1):1208-P
20. Bloomgarden Z. Sodium-glucose cotransporter 2 inhibitors and renal function-2. Journal of diabetes 2015;7(3):295-8
21. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34(9):2015-22
22. Min T, Handley J, Williams D, et al. Renal function and dapagliflozin in routine clinical practice. J Diabetes 2015;7(4):591-2
23. Vakkalagadda B, Lubin S, Reynolds L, et al. Lack of Pharmacokinetic Interaction between Saxagliptin and Dapagliflozin in Health Subjects. Diabetes 2015;64(Suppl 1):1256